{"id":4936,"date":"2025-10-27T10:13:01","date_gmt":"2025-10-27T07:13:01","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4936"},"modified":"2025-10-30T13:22:59","modified_gmt":"2025-10-30T10:22:59","slug":"avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/avidity-biosciences-enters-into-agreement-to-be-acquired-by-novartis\/","title":{"rendered":"Avidity Biosciences, Novartis Taraf\u0131ndan Sat\u0131n Al\u0131nacak"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Duchenne kas distrofisi i\u00e7in ekzon 44 atlama tedavisi geli\u015ftiren Avidity Biosciences, Novartis AG (&quot;Novartis&quot;) ile her iki \u015firketin Y\u00f6netim Kurullar\u0131 taraf\u0131ndan oybirli\u011fiyle onaylanan kesin bir birle\u015fme anla\u015fmas\u0131 imzalad\u0131\u011f\u0131n\u0131 duyurdu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sat\u0131n alma, Avidity&#039;nin erken a\u015fama hassas kardiyoloji programlar\u0131n\u0131n, halka a\u00e7\u0131k bir \u015firket olmas\u0131 beklenen SpinCo&#039;ya ayr\u0131lmas\u0131n\u0131n ard\u0131ndan ger\u00e7ekle\u015fecek. SpinCo, \u015fu anda Avidity&#039;nin ba\u015f program sorumlusu olan Kathleen Gallagher taraf\u0131ndan y\u00f6netilecek ve CEO olarak g\u00f6rev yapacak. \u015eu anda Avidity&#039;nin ba\u015f icra sorumlusu olan Sarah Boyce ise y\u00f6netim kurulu ba\u015fkan\u0131 olarak g\u00f6rev yapacak.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Novartis, Avidity&#039;nin n\u00f6robilim alan\u0131ndaki programlar\u0131n\u0131 ve geli\u015ftirme hatt\u0131n\u0131 sat\u0131n alacak ve farkl\u0131la\u015ft\u0131r\u0131lm\u0131\u015f RNA hedefleme da\u011f\u0131t\u0131m platformuna eri\u015fim sa\u011flayacak. Anla\u015fma, \u00fc\u00e7 ileri a\u015fama klinik geli\u015ftirme program\u0131n\u0131 kaps\u0131yor: Duchenne kas distrofisi (DMD) tedavisi i\u00e7in delpacibart zotadirsen (del-zota), miyotonik distrofi tip 1 (DM1) tedavisi i\u00e7in delpacibart etedesiran (del-desiran) ve fasioskapulohumeral kas distrofisi (FSHD) tedavisi i\u00e7in delpacibart braxlosiran (del-brax).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha fazla bilgi edin<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/tr\/del-zota-dmd-rna-therapy-from-avidity-biosciences-reverses-the-progression-of-disease\/\">Avidity Biosciences'in Del-Zota DMD RNA Terapisi Hastal\u0131\u011f\u0131n \u0130lerlemesini Tersine \u00c7eviriyor<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Avidity Biosciences, which is developing an exon 44 skipping therapy for Duchenne muscular dystrophy, announced that it has entered into a definitive merger agreement with Novartis AG (&#8220;Novartis&#8221;) which has been unanimously approved by the Boards of Directors of both companies. The acquisition will follow the separation of Avidity&#8217;s early-stage precision cardiology programs into SpinCo, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4938,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[126,141,127,246,447],"class_list":["post-4936","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-avidity-biosciences","tag-exon-44","tag-exon-44-skipping","tag-exon-44-skipping-therapies","tag-novartis"],"subtitle":"Novartis AG, Duchenne kas distrofisi i\u00e7in ekzon 44 atlama tedavisi geli\u015ftiren Avidity Biosciences'yi sat\u0131n alarak ileri a\u015fama n\u00f6robilim hatt\u0131n\u0131 g\u00fc\u00e7lendirmeyi kabul etti.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=4936"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4936\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/4938"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=4936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=4936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=4936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}